Effect of Acute Phase Reactants in Pathogenesis of Newly Diagnosed Type 2 Diabetic Patients and Patients under Treatment by Oral Hypoglycemic Drug for Minimum 5 Yrs

Shamim SM*
Imam Abdulrahaman Bin Faisal University, Saudi Arabia

*Corresponding author: Shamim Shaikh Mohiuddin, Imam Abdulrahaman Bin Faisal University, PO box- 1982, Dammam- 31441, Kingdom of Saudi Arabia, Saudi Arabia, Tel: 00966-562539936; Email: smohiuddin@iau.edu.sa

Abstract

Acute phase response which is predominately cytokine-mediated is observed to be closely involved in the pathogenesis of type 2 diabetes. Since maximum world populations are at high risk of developing diabetes, we tested this hypothesis by estimating circulating acute phase proteins type 2 (T-2) diabetic patients and type 2 diabetic patients under oral hypoglycemic drugs for duration of at least 5 years.

The acute phase proteins, α1-antitrypsin, α1-acid glycoprotein, ceruloplasmin and fibrinogen were estimated in the plasma in newly diagnosed 25 T-2 cases and 25 T-2 cases under oral hypoglycemic agent for at least 5 years. Thirty normal controls to match the age and sex of the test groups were also studied. The levels of these proteins were correlated with their BMI and random plasma glucose values.

In comparison with the controls, the values of all the four proteins studied were significantly elevated in the T-2 patients (p<.00001) and reduced significantly except α1-acid glycoprotein and ceruloplasmin. Interestingly, no correlation was found with BMI or the degree of hyperglycemia in either of the types. A low grade inflammatory process is definitely implicated in the pathogenesis of type 2 diabetes. This line of pathological basis should be further explored for diagnosis, management and follow up.

Keywords: α1-acid glycoprotein; α-1 antitrypsin; Fibrinogen; Ceruloplasmin

Introduction

Diabetes Mellitus is one of the most common major public health problems having worldwide distribution. It has now adopted epidemic proportions. This recent explosion of interest in the notion that chronic low grade inflammation and activation of the innate immune system are closely involved in the pathogenesis of type 2 diabetes mellitus was first proposed in 1997-98 [1]. Several studies after that have shown that circulating markers of inflammation, acute phase reactants or interleukin-6 (IL-6) are strong predictors of the development of type 2 diabetes [2,3]. α1-acid glycoprotein, α-1 antitrypsin, fibrinogen and ceruloplasmin are few of the acute phase reactants. The level of these inflammatory markers in the pathogenesis of type 2 Diabetes mellitus was of interest.
Recently, there is increasing evidence that an ongoing cytokine induced acute phase response which is sometimes called low grade inflammation, but part of a widespread activation of the innate immune system, is closely involved in the pathogenesis of type 2 diabetes mellitus and associated complications such as dyslipidemia and atherosclerosis. Elevated circulatory inflammatory markers such as C-reactive protein and interleukin-6 predict the development of type 2 diabetes mellitus and several drugs with anti-inflammatory properties both lower both acute phase reactants and glycaemia and possibly decrease the risk of developing type 2 diabetes mellitus. Age, inactivity, certain dietary components, smoking, psychological stress and low birth weight are among the risk factors for type 2 diabetes mellitus, which are also known to be associated with activated innate immunity. Activated immunity may be the common antecedent of developing type 2 diabetes mellitus [4]. Other features of type 2 diabetes mellitus such as fatigue, sleep disturbance and depression are likely to be at least partly due to hypercytokinemia and activated innate immunity.

**Material and Method**

Patients with features of previously undiagnosed diabetes were examined by the physicians. Of the confirmed cases, patients with a history of chronic inflammatory diseases, episodes of recent acute inflammation, smokers, alcoholics, women on oral contraceptive pills or any other hormones, pregnant women and patients with clinical evidence of neuropathy, nephropathy, and retinopathy were not enrolled in the study. Twenty five (25) type 2 patients between the age limit of 30-60 yrs. of either sex gave their consent to participate in the study. Twenty five (25) type 2 diabetes mellitus patients who are under treatment of oral hypoglycemic drugs for at least 5 yrs. between the age limit of 30-60 yrs. were also chosen. Type 2 was decided based only on their age and their subsequent response to insulin and oral hypoglycemic, respectively. Thirty (30) individuals were chosen from attendants of the patients to serve as controls. All exclusion criteria of the test groups were applied to the control group also. The protocol was approved by the Institutional Ethics Committee. Age, weight and height were recorded and body mass index (BMI) was calculated. Blood was collected as a random sample before the initiation of therapy in the diabetic patients and the following estimations were carried out:

- Random plasma glucose (RBS): By the glucose oxidase method on Hitachi 917 autoanlyser using Roche Kits.
- Fibrinogen assay [5]: Fibrinogen in plasma was converted to fibrin in the presence of calcium chloride. The fibrin clot was collected and digested with sodium hydroxide. Protein content of the clot was determined by the biuret method.
- Ceruloplasmin assay [6]: At pH 5.4, ceruloplasmin catalyses the oxidation of paraphenylenediamine (PPD) to yield a coloured product which is believed to correspond either to Bandrowski’s base or to Weuster’s red. The rate of formation of the coloured oxidised product is proportional to the concentration of ceruloplasmin, if a correction is made for the nonenzymatic oxidation of PPD. Simultaneous estimations were carried out with and without sodium azide, which inhibits the nonenzymatic oxidation of PPD. The difference between the results of the two assays was proportional to the ceruloplasmin concentration.
- α-1 antitrypsin assay [7]: The proteolytic enzyme trypsin hydrolyses casein, with the formation of smaller peptides. The enzyme reaction after suitable interval of time is arrested by the addition of tri-chloroacetic acid (TCA) which precipitates the proteins, but the peptides are soluble in the acid. The TCA soluble fragments are a measure of proteolytic activity of this enzyme. When the inhibitor is added to the preincubated mixture, it prevents the release of peptides by the proteolytic enzymes. Thus, the estimation of TCA soluble components in the presence and absence of inhibitor is a measure of inhibitory activity against proteolytic enzymes. The TCA soluble fragments were analysed by the method of Lowry et al. [8]. The final colour formed is a result of the reaction of the peptides with copper ions in alkali and reduction of the phosphomolybdic reagent by the presence of tyrosine and tryptophan present in the treated peptides.
- α-1 acid glycoprotein [9]: After removing heat coagulable proteins with perchloric acid, the orosomucoid which remains in the solution was precipitated by phosphotungstic acid and estimated by determining its carbohydrate content by reaction with its tyrosine residues with folinic acid reagent. Statistics The data was analysed by the student’s t test and the ANOVA test. Pearson’s coefficient was applied for correlation analysis.

**Results**

The aim of the study was to examine inflammation as a pathogenetic cause in type 2 freshly diagnosed diabetes mellitus cases. The mean age (range), BMI and the number of males: females are presented in Table 1 control group participants were so chosen as to cover the age range of the test groups. Table 2 lists the values of random blood sugar (RBS) and acute phase proteins in the three groups as mean ± SD. Test group T-2 had significant higher values of all the parameters in
Diabetes and Obesity International Journal

Shamim SM. Effect of Acute Phase Reactants in Pathogenesis of Newly Diagnosed Type 2 Diabetic Patients and Patients under Treatment by Oral Hypoglycemic Drug for Minimum 5 Yrs. Diabetes Obes Int J 2017, 2(5): 000167.

comparison with the control group. It is noteworthy that although the levels of all the acute phase markers studied were higher in the T-2 patients. This can be further appreciated in Table 3 which depicts the significance levels (p values) of the test and control groups. After treatment by oral hypoglycemic drug for 5 yrs. the level of ceruloplasmin and α1 acid glycoprotein were quite under control which can be further again depicted by the p values of the test and control groups.

| Parameters                          | Type 2 Mean ±SD | Controls Mean ±SD | Type2 under treatment Mean ±SD |
|-------------------------------------|-----------------|-------------------|--------------------------------|
| Random blood Sugar (mg/dL)          | 192.26±35.20    | 93.20±7.00        | 193.61±33.65                  |
| α1 antitrypsin (mg/dL)              | 561.16±63.00    | 349.48±114.07     | 519.38±47.80                  |
| α1 acid glycoprotein (mg/dL)        | 180.93±31.94    | 102.41±22.13      | 87.10±17.69                   |
| Ceruloplasmin (mg/dL)               | 44.05±9.03      | 25.95±4.10        | 25.73±9.94                    |
| Fibrinogen (mg/dL)                  | 571.25±82.26    | 334.34±42.19      | 581.74±79.09                  |

n= number of subjects

Table 1: Patient Characteristics.

Table 2: Levels of the acute phase proteins as Mean ± SD.

| Parameters                          | T-2 v/s Controls | T-2UT v/s Controls | T-2 v/s T-2UT |
|-------------------------------------|-----------------|-------------------|---------------|
| Random blood Sugar (mg/dL)          | < 0.0001*       | < 0.0001*         | 0.972         |
| α1 antitrypsin (mg/dL)              | < 0.0001*       | < 0.0001*         | 0.03          |
| α1 acid glycoprotein (mg/dL)        | < 0.0001*       | 0.05              | < 0.0001*     |
| Ceruloplasmin (mg/dL)               | < 0.0001*       | 0.55              | < 0.0001*     |
| Fibrinogen (mg/dL)                  | < 0.0001*       | < 0.0001*         | 0.682         |

T-2= Type 2 newly diagnosed patient
T-2 UT = Type 2 diabetic patient under treatment for minimum 5 yrs
p≤0.05 was considered significant * = statistically significant

Table 3: Significance (p value).

Discussion

The aim of this study was to examine inflammation as a pathogenetic cause in type 2 diabetes mellitus. Twenty-five type 2 newly diagnosed patients showed increased levels of α1-antitrypsin, α1-acid glycoprotein, ceruloplasmin and fibrinogen. The findings were in agreement with most of the authors who worked with acute phase proteins in type 2 diabetes [10-12]. The role of chronic low grade inflammation in the pathogenesis of type 2 diabetes seems possible beyond doubt. The most dreaded complication being that of development of atherosclerosis resulting in cardiovascular diseases. Fibrinogen is identified as an independent risk factor in the development of ischemic heart diseases.

Ceruloplasmin is known to have antioxidant action [13]. It is also an acute phase protein with a response of intermediate magnitude. Ceruloplasmin is known to stimulate cell proliferation and angiogenesis [14]. The higher levels of ceruloplasmin in type 2 as compared to controls may be due to an oxidative stress that is prevalent in type 2 diabetes [15,16]. Eduardo Ehrenwald [17] showed a very interesting feature of ceruloplasmin. The intact human ceruloplasmin which is 132 KD molecules caused increased oxidation of LDL in vitro. Starkebaum G and Harlan JM et al also showed that increased serum ceruloplasmin could generate excess oxidized LDL, and cause vascular injury by generating free radicals such as hydrogen peroxide. These findings defined the earlier notions of the antioxidant activity of
ceruloplasmin. By further investigations Eduardo Ehrenwald et al. found that the holoceruloplasmin, which is seen in serum as a 132 KD molecule, has a prooxidant effect and the action was attributed to the copper ions present in ceruloplasmin. The commercially available ceruloplasmin is a degraded product containing either 115 KD fragment or 19 KD fragment or both. These had an antioxidant effect. The works done to show that ceruloplasmin as an antioxidant used these degraded products. The antioxidant action of a commercial ceruloplasmin was observed even in the system where holoceruloplasmin oxidized LDL [17]. Hence considering ceruloplasmin as an antioxidant in vivo is debatable. The LDL oxidizing action of ceruloplasmin could probably explain at least in part of the increased risk of IHD in type 2 diabetes. Also it could not be wrong to count ceruloplasmin as an acute phase reactant whose levels are increased in type 2 diabetes.

The values of various parameters when compared between controls and type 2 patients reveal a significant increase in type 2 patients (Table-2). Even the ceruloplasmin values, although not statistically significant, were slightly higher in the type 2 patients. The mean random blood sugar (RBS) values in Type 2 newly diagnosed diabetics was 192.26±35.20 mg/dl. In spite of this huge difference, the inflammatory markers levels were higher in the type 2 patients which go to prove that the glyemic status doesn’t influence the inflammatory markers. This is in accordance with previous findings [18]. Evidence is available to say that inflammatory markers are elevated well before the clinical manifestation of hyperglycemia [19-22]. This also gives credence to the thought that activation of innate immunity is not related to hyperglycemia. But research has shown that decreasing plasma glucose levels decrease the concentration of acute phase reactants [23]. Also 2 hrs post load glucose values showed positive correlation with the inflammatory markers in few studies [18].

The underlying mechanism for the augmented acute phase response is not well understood and the stimulus for the response is unknown. A number of hypotheses have been put forward and these include insulin resistance, obesity, atherosclerosis, other diabetic complications and maladaptation of the normal innate immune response to environmental threats [24-26]. The most widely studied is the association of obesity, insulin resistance, type 2 diabetes and acute phase reactants. It has been shown that adipocytes secrete a number of proinflammatory cytokines in the postprandial state [27-29]. The term ‘diabecity’ has received attention of late for obese diabetics [30]. The ‘common soil’ theory proposed, evaluates the involvement of inflammation in the pathogenesis of diabetes and atherosclerosis. Hyperglycemia and insulin resistance could promote inflammation and inflammation may be a factor linking diabetes mellitus to the development of atherosclerosis. Elevated glucose levels promote inflammation by increasing oxidative stress, by the formation of AGEs and increased TNF (kappa B) [31,32]. In this study, the mean BMI was found to be 20.75 ± 2.27 in control and 23.03 ± 1.46 in type 2 patients. No correlation was found between BMI and acute phase reactants. Hence it can be summarized that there could be multiple pathways involved in the activation of the innate immunity system and much work needed to be done to establish either a causal role in the development of mainly type 2 diabetes.

Having demonstrated that there is an inflammatory process going on in type 2 diabetes, we next thought of estimating inflammatory markers in patients on treatment( for at least 5 years) with oral hypoglycemic drugs. Many of the drugs have been shown to have anti-inflammatory effects. Statin drugs inhibits HMG-CoA reductase and prevent atherosclerosis and inhibit the acute phase response by diminishing the deposition of LDL particles rich in cholesterol and phospholipids in macrophages and smooth muscle cells [33]. Statins were found to reduce CRP levels and did not correlate with the reduction of the lipid levels suggesting that the addition in their ability to reduce LDL, statins may also inhibit the acute phase response [34]. Freeman DJ et al showed that statin therapy also prevent diabetes mellitus. Pravastatin therapy in the West of Scotland Coronary Prevention Study resulted in a 30% reduction of risk of developing type 2 diabetes [35]. Salicylates in high doses have been known to lower glycosuria in diabetic patients [36]. Although earlier studies were contradictory, these studies has used lower aspirin doses (<3gm/day) and therapeutic duration was only for a few days. Hundal RS [37] reported that high doses of aspirin (7 gm/day) for 2 wks caused 25% reduction in fasting plasma glucose, 50% reduction in triglyceride and 15% reduction of CRP concentration independently of the changes in the plasma insulin concentration. The recently introduced oral hypoglycemic agents thiazolidinedions (Glitazone) are peroxizome proliferators activated receptor γ (PRARγ) agonist that have been regarded as insulin sensitizes through mechanisms such as altered transcription of insulin sensitive genes controlling lipogenesis, adipocytes differentiation, fatty acid uptake and GLUT 4 (Glucose Transporter 4) expression. They also have an anti-inflammatory action inhibiting cytokine production, macrophage activation and reducing CRP as well as WBC count in type 2 diabetic subjects [38-41].

Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) are also known to decrease insulin resistance in either type 1 or type 2 diabetic patients with concomitant hypertension [42]. Torlone E et al.
The text contains information about the effects of diabetes mellitus on the immune system and the role of oxidative stress in the development of type 2 diabetes. It discusses the association between type 2 diabetes and aging, and the impact of insulin resistance on the development of complications in diabetes. The text also references several studies and articles on the topic, including works by Varley, Gowanlock, Bel M, and others. The text concludes with a list of references for further reading on the subject.
17. Ehrenwald E, Chisoiom GM, Fox PL (1994) Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93(4): 1493-1501.

18. Srirahan M, Angela JR, Maria LPO, Bruce BD, Sotes SM, et al. (2002) Total sialic acid and associated elements of the metabolic syndrome in women with and without previous gestational diabetes. Diabetes Care 25(0): 1331-1335.

19. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, et al. (2003) Inflammation sensitive plasma protein, diabetes mortality and incidence of myocardial infarction and stroke: A population based study. Diabetes New York 52(2): 442-447.

20. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, et al. (1999) Markers of inflammation and prediction of diabetes mellitus in adult (Atherosclerosis Risk in Communities Study): A Cohort Study. Lancet 353(9165): 1649-1652.

21. Duncan BB, Schmidt MI, Offen BS, Wu KK, Savage PJ, et al. (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adult: The Atherosclerosis Risk In Community (ARIC) study. Diabetes Care 22(5): 767-772.

22. Pradhan AD, Manson JE, Ruai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin-6 and risk of developing type2 diabetes mellitus: JAMA 286(3): 327-334.

23. Gavella M, Lipovac V, Car A, Vocic M (2003) Serum sialic acid in subjects with impaired glucose tolerance and in newly diagnosed type 2 diabetic patient. Acta Diabetologica 40(2): 95-100.

24. Pickup JC, Crooke MA (1998) Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 41(10): 1241-1248.

25. Grimble RF (2002) Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab 5(5): 551-559.

26. Pradhan AD, Ridkar PM (2002) Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23(11): 831-834.

27. Mohammed Ali V, Goodrick S, Rawesh A, Katz DR, Miles M, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor α, in vivo. J Clin Endocrinol Metab 82(12): 4196-4200.

28. Hotamisligil GS, Amer P, Cam JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor α in human obesity and insulin resistance. J Clin Invest 95(5): 2409-2415.

29. Fried SK, Budkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: adipose tissue difference and regulation by glucocorticoids. J Clin Endocrinol Metab 83(3): 847-850.

30. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, et al. (2003) Low grade inflammation and development of type2 diabetes: The Atherosclerosis Risk in Communities study. Diabetes 52(7): 1799-1805.

31. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48(1): 1-9.

32. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complication. Nature 414(6865): 813-820.

33. Manford RS (2001) Statins and the acute phase response. N Engl J Med 344(26): 2016-2018.

34. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H (2001) Simvastatin has anti-inflammatory and antiatherosclerosis activities in depend of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21(1): 115-121.

35. Freeman DJ, Norrie J, Satter N, Neely RD, Cobbe SM, et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment in the West of Scotland Coronary Prevention Study. Circulation 103(3): 357-362.

36. Yuan M, Konstanopoulos N, Lee J, Hansen L, Li ZW, et al. (2001) Reversal of obesity and diet induced insulin resistance with salicylate or targeted disruption of ikk (beta). Science 293(5535): 1673-1677.

37. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Insuczi S, et al. (2002) Mechanism by which high dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109(10): 1321-1326.

38. Ricolle M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxizome proliferators activated receptor(gamma) is a negative regulator of macrophage activation. Nature 391(6662): 79-82.

39. Haffner SM, Greenberg AS, Westor WM, Chen H, Williams K, et al. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Gradation 106(6): 679-684.
40. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, et al. (2002) Differential effects of metformin and troglitazone on cardiovascular risk factors with type 2 Diabetes. Diabetes Care 25(3): 542-549.

41. Ebeling P, Teppo AM, Koistinen HA, Viikari J, Ronnemma T, et al. (1999) Troglitazone reduces hyperglycaemia and selective acute phase proteins in patients with type 2 diabetes. Diabetologia 42(12): 1433-1438.

42. Pollare T, Lithell H, Berne CA (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321(13): 866-872.

43. Torlone E, Britta M, Rambotti AM, Periello G, Santeusanio F, et al. (1993) Improved glycemic control after long term angiotensin converting enzyme inhibition in subjects with arterial hypertension and type 2 diabetes. Diabetes Care 16(10): 1347-1352.

44. Campus SP, Baumann H (1992) Insulin is a prominent modulator of the cytokine stimulated expression of acute phase plasma protein gene. Mol Cell Biol 12(4): 1789-1797.